# TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

> **NCT02117427** · PHASE1,PHASE2 · COMPLETED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 11 (actual)

## Conditions studied

- Chronic Kidney Disease
- End Stage Renal Disease

## Interventions

- **BIOLOGICAL:** MDGN201 TARGTEPO

## Key facts

- **NCT ID:** NCT02117427
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-27
- **Primary completion:** 2016-06-30
- **Final completion:** 2017-03-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2018-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117427, "TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02117427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*